EcoDrugPlus

Ribosomal Protein L23

Ensembl ID : ENSCPRG00005002327
Gene Symbol: RPL23
3 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L23a

Ensembl ID : ENSCPRG00005015781
Gene Symbol: RPL23A
3 Cross references
821 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L24

Ensembl ID : ENSCPRG00005010827
Gene Symbol: RPL24
3 Cross references
319 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L26

Ensembl ID : ENSCPRG00005007902
Gene Symbol: RPL26
3 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L27

Ensembl ID : ENSCPRG00005008253
Gene Symbol: RPL27
3 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L27a

Ensembl ID : ENSCPRG00005001562
Gene Symbol: RPL27A
2 Cross references
486 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L3

Ensembl ID : ENSCPRG00005019029
Gene Symbol: RPL3
3 Cross references
290 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L32

Ensembl ID : ENSCPRG00005012635
Gene Symbol: RPL32
3 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L34

Ensembl ID : ENSCPRG00005005811
Gene Symbol: RPL34
3 Cross references
356 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35

Ensembl ID : ENSCPRG00005010810
Gene Symbol: RPL35
3 Cross references
279 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35a

Ensembl ID : ENSCPRG00005012189
Gene Symbol: RPL35A
3 Cross references
501 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L36

Ensembl ID : ENSCPRG00005013297
Gene Symbol: RPL36
3 Cross references
401 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).